CRMD
CorMedix Inc.
$8.74
-2.46%
$685.7M
No data for this timeframe.
Vol
Market Cap$685.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$162.8M
Inst. Activity11 buys / 8 sells
Reddit Sentiment33° Cool
SEC Reports6
Press Releases3
Recent Activity
Jun 12, 2026
SEC
A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelming 3 sellers (net -$
INST-CLUSTER — Impact 7/10
Jun 8, 2026
SEC
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Ne
8-K — Impact 7/10
Jun 8, 2026
announcement
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
<p align="justify">PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasd
May 14, 2026
SEC
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with DefenCath sales of
8-K — Impact 7/10
Feb 4, 2026
Insider
Zelnick Kaufman Beth was granted 36,006 shares
Chief Legal Officer
Feb 4, 2026
Insider
Hurlburt Elizabeth was granted 36,006 shares
Chief Operating Officer
Feb 4, 2026
Insider
Todisco Joseph was granted 77,156 shares
Chief Executive Officer
Inst.
ROYCE & ASSOCIATES LP — DOUBLED
1,887,532 shares ($12.8M)
Price Targets
$15.20
+73.9% upside
Strong Buy
Current $8.74
Low $13.00
Median $15.00
High $19.00
5 analysts
$13.00
$19.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 27, 2026 | Needham | MAINTAIN | Buy → Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.23 ▼ -15.6% | $0.15 — $0.31 | -16% YoY | 5 |
| Next Q | $-0.09 ▼ -68.7% | $-0.16 — $-0.04 | -107% YoY | 5 |
| Current FY | $0.50 ▼ -2.2% | $0.42 — $0.56 | -75% YoY | 5 |
| Next FY | $0.09 ▼ -59.3% | $0.01 — $0.18 | -83% YoY | 5 |
Latest Reports
BULLISH
INST-CLUSTER
7/10
A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelming 3 sellers (net -$
Jun 12, 2026
BULLISH
8-K
7/10
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Ne
Jun 8, 2026
BULLISH
Press
7/10
CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of
Jun 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $40.5M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.3M | — |
| STATE STREET CORP | $14.9M | — |
| ROYCE & ASSOCIATES LP | $12.8M | DOUBLED |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 4, 2026 | Zelnick Kaufman | A | $0.00 |
| Feb 4, 2026 | Hurlburt Elizabeth | A | $0.00 |
| Feb 4, 2026 | Todisco Joseph | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $162.8M total value (24,018,790 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 11 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5,967,575 | $40.5M | 24.9% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3,129,656 | $21.3M | 13.1% | — |
| 3 | STATE STREET CORP | 2,191,843 | $14.9M | 9.1% | — |
| 4 | ROYCE & ASSOCIATES LP | 1,887,532 | $12.8M | 7.9% | DOUBLED +679.9% |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 922,200 | $6.3M | 3.8% | — |
| 6 | Alyeska Investment Group, L.P. | 850,000 | $5.8M | 3.5% | TRIM -32.7% |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 819,100 | $5.6M | 3.4% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 742,571 | $5.0M | 3.1% | — |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 602,966 | $4.1M | 2.5% | DOUBLED +199.0% |
| 10 | Trexquant Investment LP | 560,637 | $3.8M | 2.3% | TRIM -63.6% |
| 11 | GOLDMAN SACHS GROUP INC | 511,329 | $3.5M | 2.1% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 505,679 | $3.4M | 2.1% | — |
| 13 | MARSHALL WACE, LLP | 502,965 | $3.4M | 2.1% | TRIM -74.4% |
| 14 | VICTORY CAPITAL MANAGEMENT INC | 499,803 | $3.4M | 2.1% | ADD +58.7% |
| 15 | MORGAN STANLEY | 435,639 | $3.0M | 1.8% | TRIM -32.9% |
| 16 | RAYMOND JAMES FINANCIAL INC | 328,224 | $2.2M | 1.4% | — |
| 17 | AMERIPRISE FINANCIAL INC | 277,784 | $1.9M | 1.2% | — |
| 18 | CITADEL ADVISORS LLC | 276,300 | $1.9M | 1.2% | — |
| 19 | LAZARD ASSET MANAGEMENT LLC | 243,179 | $1.7M | 1.0% | — |
| 20 | CITADEL ADVISORS LLC | 242,612 | $1.6M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ROYCE & ASSOCIATES LP | DOUBLED | 242,023 | 1,887,532 | +679.9% | $12.8M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 1,966,262 | 502,965 | -74.4% | $3.4M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 314,970 | 499,803 | +58.7% | $3.4M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 648,762 | 435,639 | -32.9% | $3.0M | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 113,512 | 216,404 | +90.6% | $1.5M | 2026-Q1 |
| Daiwa Securities Group Inc. | DOUBLED | 200 | 126,400 | +63100.0% | $858.3K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 56,287 | 102,844 | +82.7% | $698.3K | 2026-Q1 |
| AVIVA PLC | ADD | 46,065 | 65,490 | +42.2% | $444.7K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 46,062 | 61,074 | +32.6% | $414.7K | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 43,951 | 56,553 | +28.7% | $384.0K | 2026-Q1 |
| Legal & General Group Plc | TRIM | 65,802 | 49,177 | -25.3% | $333.9K | 2026-Q1 |
| Concurrent Investment Advisors, LLC | ADD | 36,350 | 47,900 | +31.8% | $325.2K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 67,834 | 40,029 | -41.0% | $271.8K | 2026-Q1 |
| Allworth Financial LP | NEAR_EXIT | 69,705 | 11,140 | -84.0% | $75.6K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 123,777 | 5,739 | -95.4% | $39.0K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,034 | 1,559 | +50.8% | $10.6K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 195 | 710 | +264.1% | $4.8K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 61,555 | 581 | -99.1% | $3.9K | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 1,385 | 297 | -78.6% | $2.0K | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 3,473,494 | 1,966,262 | -43.4% | $22.9M | 2025-Q4 |
| Alyeska Investment Group, L.P. | TRIM | 1,262,979 | 850,000 | -32.7% | $9.9M | 2025-Q4 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 235,317 | 314,970 | +33.8% | $3.7M | 2025-Q4 |
| Assenagon Asset Management S.A. | ADD | 224,061 | 302,508 | +35.0% | $3.5M | 2025-Q4 |
| ROYCE & ASSOCIATES LP | TRIM | 441,312 | 242,023 | -45.2% | $2.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 128,555 | 181,106 | +40.9% | $2.1M | 2025-Q4 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Zelnick Kaufman Beth | Chief Legal Officer | AWARD | 36,006 | — | — |
| Feb 4, 2026 | Hurlburt Elizabeth | Chief Operating Officer | AWARD | 36,006 | — | — |
| Feb 4, 2026 | Todisco Joseph | Chief Executive Officer | AWARD | 77,156 | — | — |
6 SEC filing reports analyzed. Sentiment: 6 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.3/10.
BULLISH
INST-CLUSTER
7/10
A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelmi
Jun 12, 2026
BULLISH
8-K
7/10
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district cour
Jun 8, 2026
BULLISH
8-K
7/10
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 dilut
May 14, 2026
BULLISH
8-K
8/10
CorMedix announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin
Apr 27, 2026
BULLISH
8-K
8/10
CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCa
Mar 5, 2026
BULLISH
7/10
CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity
Jun 8, 2026
BULLISH
8/10
CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungi
Apr 27, 2026
BULLISH
8/10
CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) a
Mar 5, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.20 mean target
+73.9% upside
Strong Buy (1.60)
$13.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $8.74 |
| Target Low | $13.00 |
| Target Mean | $15.20 |
| Target Median | $15.00 |
| Target High | $19.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.23 | $0.15 | $0.31 | -16.4% | -15.6% | 3↑ 2↓ | $0.1B | 140.6% | 5 |
| Next Q 2026-09-30 |
$-0.09 | $-0.16 | $-0.04 | -107.5% | -68.7% | 1↑ 1↓ | $0.1B | -48.3% | 5 |
| Current FY 2026-12-31 |
$0.50 | $0.42 | $0.56 | -75.5% | -2.2% | 3↑ 3↓ | $0.3B | 7.2% | 5 |
| Next FY 2027-12-31 |
$0.09 | $0.01 | $0.18 | -82.8% | -59.3% | 0↑ 4↓ | $0.3B | -14.7% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.234 | |
| 7d ago | $0.240 | -0.006 |
| 30d ago | $0.277 | -0.043 |
| 60d ago | $0.358 | -0.124 |
| 90d ago | $0.363 | -0.129 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$CRMD - *Leans in*
▲ 1
💬 1
⚡ 0.5
Jun 8, 2026
announcement
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
<p align="justify">PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States C
May 19, 2026
short_volume
Short Volume: CRMD — 64.4% short (0.4M / 0.6M)
Short: 398,432 | Exempt: 310 | TRF Vol: 618,606 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CRMD — 58.2% short (0.5M / 0.8M)
Short: 453,501 | Exempt: 1,624 | TRF Vol: 779,475 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
<p align="justify">PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be p
May 15, 2026
short_volume
Short Volume: CRMD — 61.2% short (0.5M / 0.9M)
Short: 532,019 | Exempt: 5,490 | TRF Vol: 870,007 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>‒ Q1 2026 Net Revenue of </em><em>$127.4 million</em><em> ‒</em></p>
May 14, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-14
May 11, 2026
short_volume
Short Volume: CRMD — 55.2% short (0.3M / 0.5M)
Short: 281,629 | Exempt: 2,224 | TRF Vol: 509,777 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
<p align="justify">PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its f
May 4, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
fda
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
<p align="center">– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
Apr 27, 2026
short_volume
Short Volume: CRMD — 60.3% short (0.4M / 0.7M)
Short: 397,582 | Exempt: 448 | TRF Vol: 659,306 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: CRMD — 58.7% short (0.3M / 0.5M)
Short: 311,596 | Exempt: 14,678 | TRF Vol: 530,642 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
other
CorMedix to Participate in Needham Virtual Healthcare Conference
<p align="justify">PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on